Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1041-1060 of 1,694 trials

HER2-Positive Gastric Cancer: Trastuzumab Deruxtecan Study

We are testing a new treatment combining Trastuzumab Deruxtecan with chemotherapy for patients with advanced HER2-positive gastric or GEJ cancer. The goal is to see if this combination works better than the current standard treatment.

Metastatic Gastric Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Autoimmune Hemolytic Anemia: Anticoagulation Study

We are testing whether prolonged anticoagulation therapy can help prevent blood clots in patients with autoimmune hemolytic anemia. This study will also look at how well patients tolerate the treatment and the timing of any clotting events.

Autoimmune Hemolytic Anemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInternal Medicine

Lanreotide and Metformin for Advanced Carcinoids

We are studying the safety of a new treatment combining Lanreotide and Metformin for patients with advanced gastrointestinal or lung carcinoids. This trial aims to understand how well this combination works and its effects on symptoms.

Advanced Progressive Gastro-Intestinal or Lung Carcinoids>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Severe Influenza: Dexamethasone vs. Placebo

We are studying whether dexamethasone can help patients with severe influenza recover better than a placebo. The trial will assess hospitalization rates, safety, and other health impacts.

H1N1 Influenza>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Axial Spondyloarthritis: NSAIDs vs. Biosimilar TNF Blockers

We are comparing the effectiveness of high-dose NSAIDs and a biosimilar TNF blocker for patients with axial spondyloarthritis who haven't responded to NSAIDs. The study will also look at side effects and inflammation levels.

Axial Spondyloarthritis3-6 monthsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Cariprazine for Adolescents with Schizophrenia

We are studying the safety and tolerability of cariprazine in adolescents aged 13 to under 18 with schizophrenia. This trial aims to see how well the medication works and its impact on health-related outcomes.

Schizophrenia>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsPsychiatry

Hormonal Treatment for Adolescents with Gender Dysphoria

We are studying the effects of starting hormonal treatment at age 14 on the well-being of adolescents with gender dysphoria. This research aims to assess both the effectiveness and safety of the treatment as they transition into adulthood.

Gender Dysphoria>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyPsychiatry

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Scabies Treatment: Testing Permethrin Cream

We are studying the effectiveness of a new higher-concentration permethrin cream for treating scabies in adults and children. The trial aims to see if this treatment works better than the standard cream and how safe it is.

Scabies>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInfectious Diseases

Alternative Antibiotics for Resistant UTIs

We are testing new oral antibiotics for patients with febrile urinary tract infections caused by resistant bacteria. The goal is to see if these alternatives are as safe as current treatments.

Urinary Tract Infection (UTI) from Resistant Bacteria>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInfectious DiseasesUrology

Type 1 Diabetes: Diamyd Study

We are investigating whether the drug Diamyd can help preserve insulin production in adolescents and adults recently diagnosed with type 1 diabetes. The study will also look at the safety of Diamyd compared to a placebo.

Type 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Relapsed or Refractory PCNSL: Emavusertib Study

We are studying the safety and effectiveness of a new oral medication, emavusertib, for patients with relapsed or refractory primary central nervous system lymphoma. This trial also explores its use alongside another treatment, ibrutinib.

Hematological MalignancyPrimary Central Nervous System Lymphoma (PCNSL)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Early-Stage Colon Cancer: NICHE Trial for Immunotherapy

We are studying a new immunotherapy treatment for patients with early-stage colon cancer to see if it can reduce tumors before surgery. The trial also aims to identify biomarkers that may help tailor treatments and improve patient outcomes.

Colon or Rectosigmoid Adenocarcinoma≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Acute Pyelonephritis: Short vs. Long Antibiotic Treatment

We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.

Kidney Infection (Pyelonephritis)Kidney Transplant Recipients>2 yearsMonitoring phase (IV)Standard MedicinesInfectious DiseasesNephrologyUrology

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine

Norfloxacin for Portal Hypertension in Decompensated Cirrhosis

We are studying whether norfloxacin can lower portal hypertension in patients with decompensated cirrhosis. The trial also looks at its effects on liver-related complications and overall patient well-being.

Portal HypertensionDecompensated Cirrhosis3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesGastroenterologyHepatology

Portosinusoidal Vascular Disorder: Edoxaban Study

We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.

Porto-Sinusoidal Vascular Disorder>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiology

Rimegepant for Migraine: Effects on Obesity

We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.

ObesityMigraine6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyNeurology

HIV-1 Treatment: High-Dose Antiretroviral Drugs

We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.

HIV Infection6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious Diseases

Breast Cancer: Palbociclib and Fulvestrant Combination

We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology